Philip M. Arlen
Directeur Général chez Precision Biologics, Inc.
Profil
Philip M.
Arlen is the President, Chief Executive Officer & Director at Precision Biologics, Inc. He was previously the President, Chief Executive Officer & Director at Neogenix Oncology, Inc. for a brief period in 2012.
Prior to that, he worked as a Principal at the National Cancer Institute and Walter Reed National Military Medical Center.
Arlen received his undergraduate degree from Emory University and his doctorate from Georgia Health Sciences University.
Postes actifs de Philip M. Arlen
| Sociétés | Poste | Début |
|---|---|---|
Precision Biologics, Inc.
 Precision Biologics, Inc. Drugstore ChainsRetail Trade Precision Biologics, Inc. develops therapeutic and diagnostic products for the early detection and treatment of cancer. Its antibody drug candidates and diagnostics are designed to detect and target the tumor without destroying healthy cells. The company was founded in February 2012 and is headquartered in Dallas, TX. | Directeur Général | 01/09/2012 |
Anciens postes connus de Philip M. Arlen
| Sociétés | Poste | Fin |
|---|---|---|
National Cancer Institute
 National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Corporate Officer/Principal | - |
| Walter Reed National Military Medical Center | Corporate Officer/Principal | - |
Neogenix Oncology, Inc.
 Neogenix Oncology, Inc. Medical SpecialtiesHealth Technology Founded in December 2003, Neogenix Oncology is a clinical stage biotechnology company focused on developing therapeutic and diagnostic products for the early detection and treatment of cancer. The company's antibody drug candidates and diagnostics are designed to detect and target the tumor without destroying healthy cells. Neogenix Oncology is uniquely positioned to create innovative therapeutics through the use of proprietary cancer vaccines, several of which have demonstrated success in human trials. By marrying this platform with today's breakthrough technologies, the company is developing antibody therapeutics that could change the way it detects and treats cancer. | Directeur Général | - |
Formation de Philip M. Arlen
| Emory University | Undergraduate Degree |
| Georgia Health Sciences University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Neogenix Oncology, Inc.
Neogenix Oncology, Inc. Medical SpecialtiesHealth Technology Founded in December 2003, Neogenix Oncology is a clinical stage biotechnology company focused on developing therapeutic and diagnostic products for the early detection and treatment of cancer. The company's antibody drug candidates and diagnostics are designed to detect and target the tumor without destroying healthy cells. Neogenix Oncology is uniquely positioned to create innovative therapeutics through the use of proprietary cancer vaccines, several of which have demonstrated success in human trials. By marrying this platform with today's breakthrough technologies, the company is developing antibody therapeutics that could change the way it detects and treats cancer. | Health Technology |
National Cancer Institute
National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Miscellaneous |
| Walter Reed National Military Medical Center | |
Precision Biologics, Inc.
Precision Biologics, Inc. Drugstore ChainsRetail Trade Precision Biologics, Inc. develops therapeutic and diagnostic products for the early detection and treatment of cancer. Its antibody drug candidates and diagnostics are designed to detect and target the tumor without destroying healthy cells. The company was founded in February 2012 and is headquartered in Dallas, TX. | Retail Trade |